Giant Biogene Holding Co (HKSE:02367) Accounts Receivable : HK$89 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Giant Biogene Holding Co's accounts receivables for the quarter that ended in Dec. 2023 was HK$89 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Giant Biogene Holding Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 7.72.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Giant Biogene Holding Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$3.71.

Giant Biogene Holding Co Accounts Receivable Historical Data

The historical data trend for Giant Biogene Holding Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Accounts Receivable Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

19.71

65.46

81.28

62.14

88.73

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Receivable	Get a 7-Day Free Trial			81.28	-	62.14	99.55	88.73

Giant Biogene Holding Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Giant Biogene Holding Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Giant Biogene Holding Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	88.725	/	2098.355	*	91
=	7.72

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Giant Biogene Holding Co's accounts receivable are only considered to be worth 75% of book value:

Giant Biogene Holding Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4133.144	+	0.75 * 88.725	+	0.5 * 219.237	-	658.486
-	0	-	9.746)	/	981.638
=	3.71

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Giant Biogene Holding Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Executives

Refulgence Holding Limited	2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd	2101 Beneficial owner
Fan Daidi	2201 Interest of corporation controlled by you
Yan Jianya	2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Yan Jianya	2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited	2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines